Key facts
- This page summarizes Steven L. Shea's Form 4 filing for BLONDER TONGUE LABORATORIES INC (BDRL).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 03 Jun 2022, 16:30.
Steven L. Shea - 01 Jun 2022 Form 4 Insider Report for BLONDER TONGUE LABORATORIES INC (BDRL)
- Reporting relationship
- Director
- Issuer ticker
- BDRL
- Reported as of
- 01 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Jun 2022, 16:30:04 UTC
- Prior SEC filing
- 08 Apr 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Steven L. Shea by Eric Skolnik Under Power of Attorney
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Steven L. Shea filed Form 4 for BLONDER TONGUE LABORATORIES INC (BDRL) on 03 Jun 2022.
Change
- Previous filing in this sequence was filed on 08 Apr 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BDRL
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +20,000
- Change %
- Price
- $0.000000
- Shares after
- 20,000
- Date
- 01 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock par value $0.001
- Underlying amount
- 20,000
- Exercise price
- $0.3900
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The stock option was granted under the 2016 Director Equity Incentive Plan.
Footnote F2
The exercise price equals the fair market value (equal to the closing price as reported on the NYSE American) of the common stock on the grant date.
Footnote F3
The stock option vests on October 1, 2022.